Listed

GRUPO SIMEC, S.A.B. de C.V.: Form 20-F for the period ended Dec 31, 2023

Filed with the SEC on Nov 18, 2024 and accepted by EDGAR at Nov 15, 2024, 19:11 ET.

Share

Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2023-12-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue12 months2023-01-01 to 2023-12-31MXN 41.14bnifrs-full:Revenue
Cost of revenue12 months2023-01-01 to 2023-12-31MXN 31.10bnifrs-full:CostOfSales
Gross profit12 months2023-01-01 to 2023-12-31MXN 10.04bnifrs-full:GrossProfit
Income tax12 months2023-01-01 to 2023-12-31MXN 1.74bnifrs-full:IncomeTaxExpenseContinuingOperations
Net income12 months2023-01-01 to 2023-12-31MXN 4.28bnifrs-full:ProfitLossAttributableToOwnersOfParent
Basic EPS12 months2023-01-01 to 2023-12-31MXN 9.28ifrs-full:BasicEarningsLossPerShare
Operating cash flow12 months2023-01-01 to 2023-12-31MXN 4.26bnifrs-full:CashFlowsFromUsedInOperatingActivities
Capital expenditure12 months2023-01-01 to 2023-12-31MXN 2.49bnifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
Cash and equivalentsAt period end2023-12-31MXN 23.58bnifrs-full:CashAndCashEquivalents
Current assetsAt period end2023-12-31MXN 41.74bnifrs-full:CurrentAssets
Total assetsAt period end2023-12-31MXN 66.79bnifrs-full:Assets
Current liabilitiesAt period end2023-12-31MXN 12.97bnifrs-full:CurrentLiabilities
Total liabilitiesAt period end2023-12-31MXN 16.98bnifrs-full:Liabilities
Shareholders' equityAt period end2023-12-31MXN 49.78bnifrs-full:EquityAttributableToOwnersOfParent
Shares outstandingAt period end2023-12-31461,676,539 sharesdei:EntityCommonStockSharesOutstanding

Source: SEC EDGAR, the filing index for accession 0001213900-24-099265. Last ingested by Listed: Oct 29, 2026, 06:05 ET. Listed shows no prices and gives no investment advice.